Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Lockhart, A Craig, Bauer, Todd M., Aggarwal, Charu, Lee, Carrie B., Harvey, R Donald, Cohen, Roger B., Sedarati, Farhad, Nip, Tsz Keung, Faessel, Hélène, Dash, Ajeeta B., Dezube, Bruce J., Faller, Douglas V., Dowlati, Afshin
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510847/
https://ncbi.nlm.nih.gov/pubmed/29781056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0610-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados